



*Trichostrongylus* spp.  
*Cooperia* spp.  
*Ostertagia* spp. (except inhibited *Ostertagia* larvae in cattle)  
*Haemonchus* spp.  
*Nematodirus* spp.  
*Bunostomum* spp.  
*Oesophagostomum* spp.  
*Chabertia* spp.

### 3.3 Contraindications

Animals must not be treated within a period of 14 days before or after treatment with organophosphorus compounds.

### 3.4 Special warnings

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).

Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Care should be taken to estimate accurately the liveweight of animals to be treated. After treatment animals should be moved to clean pasture in order to prevent re-infection.

Veterinary advice should be sought:

- a) On appropriate dosing programmes and stock management to achieve adequate parasite control, and to reduce the likelihood of anthelmintic resistance developing.
- b) If the product does not achieve the desired clinical effect since other diseases, nutritional disturbances or anthelmintic resistance might be involved.

Special precautions to be taken by the person administering the veterinary medicinal product to animals.

Do not eat, drink or smoke when using this product.

Care should be taken to avoid accidental self-injection: may cause irritation at site of injection. Wash splashes from eyes and skin immediately. If irritation persists, seek medical advice and show the package leaflet or the label to the physician. Remove any contaminated clothing immediately. Wash hands and exposed skin after handling this product and before meals. Levamisole can cause idiosyncratic reactions and serious blood disorders in a very small number of people. If symptoms such as dizziness, nausea, vomiting or abdominal discomfort are experienced when using this product, or sore mouth, throat or fever occur shortly afterwards, then seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Target species: Cattle and sheep.

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Injection site reaction <sup>1</sup>
---	--------------------------------------

<sup>1</sup> Normally non-irritant and should resolve naturally in a short period of time.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

The veterinary medicinal product can be safely administered to pregnant or lactating animals.

However care should be taken when treating heavily pregnant animals and animals under stress from adverse weather conditions, poor nutrition, penning, handling etc.

### 3.8 Interaction with other medicinal products and other forms of interaction

Levamisole activity is not affected by benzimidazole resistance.

### **3.9 Administration routes and dosage**

The veterinary medicinal product should be administered by subcutaneous injection at a rate of 7.5 mg Levamisole per kg bodyweight. Usual aseptic precautions should be observed. Cattle should be dosed at a rate of 1 ml of product per 10 kg bodyweight and sheep at a rate of 0.5 ml per 5 kg bodyweight. To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. The veterinary medicinal product is to be administered using a draw off needle.

Divide large doses between two or more injection sites.

Do not mix with any other products before administration except if premixing is done by a veterinary surgeon or a pharmacist.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

Levacide Injection is safe for use in cattle and sheep at the recommended dosages. However, if recommended doses are exceeded animals may exhibit signs of impaired motor functions such as muscle tremors and increased salivation, which are of a temporary nature.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Cattle

Meat and offal: 28 days

Sheep

Meat and offal: 15 days

Not authorised for use in cattle and sheep producing milk for human consumption.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code:**

QP52AE01

### **4.2 Pharmacodynamics**

Levamisole hydrochloride is the laevo isomer of dl 2, 3, 5, 6-Tetrahydro-6- phenyl-imidazo(2,1-b) thiazole hydrochloride. Levamisole was found to be active against adult and immature gastro-intestinal and pulmonary nematodes when administered to experimentally infected animals by the oral, subcutaneous, intramuscular or

intraperitoneal routes. It is thought to act by paralysing the susceptible parasites which are then expelled from the alimentary canal.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

None known.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.  
Shelf life after first opening the immediate packaging: use immediately.

### **5.3 Special precautions for storage**

Do not store above 25 °C.  
Store in the original package, in an upright position.  
Protect from light.

In order to minimise the risk of infection, needles should be changed as frequently as possible.

Following withdrawal of the first dose, use the product immediately.

Discard any unused material after first opening the primary packaging.

### **5.4 Nature and composition of immediate packaging**

The veterinary medicinal product is supplied in glass vials in a cardboard box, sealed with bromobutyl bung and aluminium seals.

Package size:

- 1 x 100 ml vial in a cardboard box.
- 1 x 250 ml vial in a cardboard box.
- 1 x 500 ml vial in a cardboard box.
- 1 x Protective plastic container and 6 x 500 ml vials in a cardboard box.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Norbrook Laboratories Limited

**7. MARKETING AUTHORISATION NUMBER**

Vm 02000/4049

**8. DATE OF FIRST AUTHORISATION**

27 April 1983

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

December 2025

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*  
Approved: 20 April 2026